{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:02:19Z","timestamp":1785855739415,"version":"3.56.0"},"reference-count":116,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>Neurodegenerative disorders involve progressive dysfunction and loss of synapses and neurons and brain atrophy, slowly declining memories and cognitive skills, throughout a long process. Alzheimer\u2019s disease (AD), the leading neurodegenerative disorder, suffers from a lack of effective therapeutic drugs. Decades of efforts targeting its pathologic hallmarks, amyloid plaques and neurofibrillary tangles, in clinical trials have produced therapeutics with marginal benefits that lack meaningful clinical improvements in cognition. Delivering meaningful clinical therapeutics to treat or prevent neurodegenerative disorders thus remains a great challenge to scientists and clinicians. Emerging evidence, however, suggests that dysfunction of various synaptogenic signaling pathways participates in the neurodegenerative progression, resulting in deterioration of operation\/structure of the synaptic networks involved in cognition. These derailed endogenous signaling pathways and disease processes are potential pharmacological targets for the therapies. Therapeutics with meaningful clinical benefit in cognition may depend on the effectiveness of arresting and reversing the neurodegenerative process through these targets. In essence, promoting neuro-regeneration may represent the only option to recover degenerated synapses and neurons. These potential directions in clinical trials for AD therapeutics with meaningful clinical benefit in cognitive function are summarized and discussed.<\/jats:p>","DOI":"10.3233\/jad-240479","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:53:42Z","timestamp":1729248822000},"page":"S263-S274","source":"Crossref","is-referenced-by-count":8,"title":["Treating Alzheimer\u2019s Disease: Focusing on Neurodegenerative Consequences"],"prefix":"10.1177","volume":"101","author":[{"given":"Miao-Kun","family":"Sun","sequence":"first","affiliation":[{"name":"Synaptogenix, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Alkon","sequence":"additional","affiliation":[{"name":"Synaptogenix, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240479_ref1","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 17, 326\u2013406."},{"key":"10.3233\/JAD-240479_ref2","doi-asserted-by":"crossref","first-page":"e12385","DOI":"10.1002\/trc2.12385","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240479_ref3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240479_ref4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.17219\/acem\/171379","article-title":"Lecanemab (Leqembi) is not the right drug for patients with Alzheimer\u2019s disease","volume":"32","author":"Kurkinen","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"10.3233\/JAD-240479_ref5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The search for clarity regarding \u201cclinically meaningful outcomes\u201d in Alzheimer disease clinical trials: CLARITY-AD and Beyond","volume":"16","author":"Tarawneh","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240479_ref6","doi-asserted-by":"crossref","first-page":"102203","DOI":"10.1016\/j.arr.2024.102203","article-title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and network meta-analysis","volume":"94","author":"Terao","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240479_ref7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tins.2019.03.003","article-title":"A unifying hypothesis for Alzheimer\u2019s disease: From plaques to neurodegeneration","volume":"42","author":"Edwards","year":"2019","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-240479_ref8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.114.512.797","article-title":"The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects","volume":"114","author":"Blessed","year":"1968","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-240479_ref9","first-page":"S1064","article-title":"Neuroplasticity: The critical issue for Alzheimer\u2019s disease and links to obesity and depression","volume":"15","author":"Ashford","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-240479_ref10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.3233\/JAD-240479_ref11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-240479_ref12","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240479_ref13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-240479_ref14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrd.2017.155","article-title":"Tau-based therapies in neurodegeneration: Opportunities and challenges","volume":"16","author":"Li","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-240479_ref15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pneurobio.2016.01.003","article-title":"Astrocytes as new targets to improve cognitive functions","volume":"144","author":"Dall\u00e9rac","year":"2016","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JAD-240479_ref16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/cdd.2008.172","article-title":"Astroglia in dementia and Alzheimer\u2019s disease","volume":"16","author":"Rodriguez","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.3233\/JAD-240479_ref17","doi-asserted-by":"crossref","first-page":"eaaw0843","DOI":"10.1126\/science.aaw0843","article-title":"Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer\u2019s disease","volume":"371","author":"Nakamura","year":"2021","journal-title":"Science"},{"key":"10.3233\/JAD-240479_ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-240479_ref19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.neuron.2005.05.006","article-title":"Dendritic spine geometry: Functional implication and regulation","volume":"46","author":"Hayashi","year":"2005","journal-title":"Neuron"},{"key":"10.3233\/JAD-240479_ref20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1523\/JNEUROSCI.5209-10.2011","article-title":"PKC \u025b activation prevents synaptic loss, A\u03b2 elevation, and cognitive deficits in Alzheimer\u2019s disease transgenic mice","volume":"31","author":"Hongpaisan","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240479_ref21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/341149a0","article-title":"Molecular cloning and expression of brain-derived neurotrophic factor","volume":"341","author":"Leibrock","year":"1989","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref22","doi-asserted-by":"crossref","first-page":"eabj8658","DOI":"10.1126\/sciadv.abj8658","article-title":"Neuronal C\/EBPbeta\/AEP pathway shortens life span via selective GABAnergic neuronal degeneration by FOXO repression","volume":"8","author":"Xia","year":"2022","journal-title":"Sci Adv"},{"key":"10.3233\/JAD-240479_ref23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archneur.59.10.1524","article-title":"Glial cells under physiologic and pathologic conditions","volume":"59","author":"Kurosinski","year":"2002","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-240479_ref24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/hsz-2021-0330","article-title":"Brothers in arms: proBDNF\/BDNF and sAPPalpha\/Abeta-signaling and their common interplay with ADAM10, TrkB, p75NTR, sortilin, and sorLA in the progression of Alzheimer\u2019s disease","volume":"403","author":"Eggert","year":"2021","journal-title":"Biol Chem"},{"key":"10.3233\/JAD-240479_ref25","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.cell.2023.08.039","article-title":"Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer\u2019s disease pathology","volume":"186","author":"Mathys","year":"2023","journal-title":"Cell"},{"key":"10.3233\/JAD-240479_ref26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fncel.2019.00135","article-title":"Mechanisms that modulate and diversify BDNF functions: Implications for hippocampal synaptic plasticity","volume":"13","author":"De Vincenti","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JAD-240479_ref27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0896-6273(91)90273-3","article-title":"BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer\u2019s disease","volume":"7","author":"Phillips","year":"1991","journal-title":"Neuron"},{"key":"10.3233\/JAD-240479_ref28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199907000-00007","article-title":"BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies","volume":"58","author":"Ferrer","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-240479_ref29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","article-title":"BDNF signaling in context: From synaptic regulation to psychiatric disorders","volume":"185","author":"Wang","year":"2022","journal-title":"Cell"},{"key":"10.3233\/JAD-240479_ref30","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1038\/s41598-020-65531-x","article-title":"Human BDNF\/TrkB variants impair hippocampal synaptogenesis and associate with neurobehavioural abnormalities","volume":"10","author":"Sonoyama","year":"2020","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-240479_ref31","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s12035-018-1283-6","article-title":"Brain-derived neurotrophic factor in brain disorders: Focus on neuroinflammation","volume":"56","author":"Lima Giacobbo","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-240479_ref32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12974-017-0930-6","article-title":"Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis","volume":"14","author":"Xu","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-240479_ref33","doi-asserted-by":"crossref","first-page":"104540","DOI":"10.1016\/j.nbd.2019.104540","article-title":"Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology","volume":"132","author":"Ginsberg","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-240479_ref34","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/alz.12576","article-title":"Quantifying longitudinal cognitive resilience to Alzheimer\u2019s disease and other neuropathologies","volume":"18","author":"Wagner","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240479_ref35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13024-023-00632-5","article-title":"The Q\/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer\u2019s disease","volume":"18","author":"Wright","year":"2023","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-240479_ref36","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1073\/pnas.0901402106","article-title":"Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease","volume":"106","author":"Blurton-Jones","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240479_ref37","doi-asserted-by":"crossref","first-page":"e907","DOI":"10.1038\/tp.2016.186","article-title":"Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer\u2019s disease","volume":"6","author":"Jiao","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JAD-240479_ref38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer\u2019s disease","volume":"15","author":"Nagahara","year":"2009","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240479_ref40","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","article-title":"Mild cognitive impairment","volume":"367","author":"Gauthier","year":"2006","journal-title":"Lancet"},{"key":"10.3233\/JAD-240479_ref41","unstructured":"FDA (2018) Early Alzheimer\u2019s disease: Developing drugs for treatment guidance for industry."},{"key":"10.3233\/JAD-240479_ref42","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for Alzheimer disease-The FDA\u2019s perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.3233\/JAD-240479_ref43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/cells13030237","article-title":"A systematic review on drugs acting as nicotinic acetylcholine receptor agonists in the treatment of dementia","volume":"13","author":"Crestini","year":"2024","journal-title":"Cells"},{"key":"10.3233\/JAD-240479_ref44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41586-021-04169-9","article-title":"Local circuit amplification of spatial selectivity in the hippocampus","volume":"601","author":"Geiller","year":"2022","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature15257","article-title":"Labelling and optical erasure of synaptic memory traces in the motor cortex","volume":"525","author":"Hayashi-Takagi","year":"2015","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnsyn.2020.00036","article-title":"Dendritic spine plasticity: Function and mechanisms","volume":"12","author":"Runge","year":"2020","journal-title":"Front Synaptic Neurosci"},{"key":"10.3233\/JAD-240479_ref47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00401-009-0536-x","article-title":"Synaptic degeneration in Alzheimer\u2019s disease","volume":"118","author":"Arendt","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-240479_ref48","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer\u2019s disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"10.3233\/JAD-240479_ref49","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11910-014-0498-9","article-title":"The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia","volume":"14","author":"Vandenberghe","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.3233\/JAD-240479_ref50","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240479_ref51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1590\/1980-5764-dn-2021-0097","article-title":"45 Years of the mini-mental state examination (MMSE): A perspective from Ibero-America","volume":"l16","author":"Gallegos","year":"2022","journal-title":"Dement Neuropsychol"},{"key":"10.3233\/JAD-240479_ref52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and responsiveness in pre-dementia populations. A narrative review","volume":"63","author":"Kueper","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240479_ref53","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240479_ref54","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","article-title":"Determining clinically meaningful decline in preclinical Alzheimer disease","volume":"93","author":"Insel","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref55","doi-asserted-by":"crossref","first-page":"e1142","DOI":"10.1212\/WNL.0000000000200817","article-title":"Clinically relevant changes for cognitive outcomes in preclinical and prodromal cognitive stages: Implications for clinical Alzheimer trials","volume":"99","author":"Borland","year":"2022","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-022-04912-w","article-title":"Molecular landscapes of human hippocampal immature neurons across lifespan","volume":"607","author":"Zhou","year":"2022","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref57","doi-asserted-by":"crossref","first-page":"104807","DOI":"10.1016\/j.archger.2022.104807","article-title":"Cognitive stimulation and cognitive results in older adults: A systematic review and meta-analysis","volume":"104","author":"G\u00f3mez-Soria","year":"2023","journal-title":"Arch Gerontol Geriatr"},{"key":"10.3233\/JAD-240479_ref58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00441-017-2782-x","article-title":"BDNF effects on dendritic spine morphology and hippocampal function","volume":"373","author":"von Bohlen Und Halbach","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.3233\/JAD-240479_ref59","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1093\/brain\/awad100","article-title":"Determinants of cognitive and brain resilience to tau pathology: A longitudinal analysis","volume":"146","author":"Bocancea","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JAD-240479_ref60","doi-asserted-by":"crossref","first-page":"637002","DOI":"10.3389\/fnagi.2021.637002","article-title":"Structural network efficiency predicts resilience to cognitive decline in elderly at risk for Alzheimer\u2019s disease","volume":"13","author":"Fischer","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240479_ref61","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2023.15231","article-title":"Sedentary behavior and incident dementia among older adults","volume":"330","author":"Raichlen","year":"2023","journal-title":"JAMA"},{"key":"10.3233\/JAD-240479_ref62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-023-02811-z","article-title":"NREM sleep as a novel protective cognitive reserve factor in the face of Alzheimer\u2019s disease pathology","volume":"21","author":"Zavecz","year":"2023","journal-title":"BMC Med"},{"key":"10.3233\/JAD-240479_ref63","doi-asserted-by":"crossref","first-page":"102162","DOI":"10.1016\/j.arr.2023.102162","article-title":"Lifestyle strategies to promote proteostasis and reduce the risk of Alzheimer\u2019s disease and other proteinopathies","volume":"93","author":"Almeida","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240479_ref64","doi-asserted-by":"crossref","first-page":"725914","DOI":"10.3389\/fnagi.2021.725914","article-title":"Association between components of cognitive reserve and serum BDNF in healthy older adults","volume":"13","author":"Collins","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240479_ref65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000530269","article-title":"The role of intermittent fasting and dieting on cognition in adult population: A systematic review of the randomized controlled trials","volume":"32","author":"Senderovich","year":"2023","journal-title":"Med Princ Pract"},{"key":"10.3233\/JAD-240479_ref66","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/ijerph19031216","article-title":"Physical activity improves cognition and activities of daily Living in adults with Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Zhou","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.3233\/JAD-240479_ref67","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.7326\/M23-1603","article-title":"Clinical effectiveness of cognitively enhanced Tai Ji Quan training on global cognition and dual-task performance during walking in older adults with mild cognitive impairment or self-reported memory concerns: A randomized controlled trial","volume":"176","author":"Li","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-240479_ref68","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJMoa2302368","article-title":"Trial of the MIND diet for prevention of cognitive decline in older persons","volume":"389","author":"Barnes","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240479_ref69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-023-01164-2","article-title":"The beneficial effect on cognition of noninvasive brain stimulation intervention in patients with dementia: A network meta-analysis of randomized controlled trials","volume":"15","author":"Tseng","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240479_ref70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cell.2019.02.014","article-title":"Multi-sensory gamma stimulation ameliorates Alzheimer\u2019s-associated pathology and improves cognition","volume":"177","author":"Martorell","year":"2019","journal-title":"Cell"},{"key":"10.3233\/JAD-240479_ref71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/joim.13755","article-title":"Audiovisual gamma stimulation for the treatment of neurodegeneration","volume":"295","author":"Blanco-Duque","year":"2024","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-240479_ref72","doi-asserted-by":"crossref","first-page":"1095081","DOI":"10.3389\/fnagi.2022.1095081","article-title":"An update on the use of gamma (multi)sensory stimulation for Alzheimer\u2019s disease treatment","volume":"14","author":"Manippa","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240479_ref73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.brs.2023.04.001","article-title":"The impact of gamma transcranial alternating current stimulation (tACS) on cognitive and memory processes in patients with mild cognitive impairment or Alzheimer\u2019s disease: A literature review","volume":"16","author":"Nissim","year":"2023","journal-title":"Brain Stimul"},{"key":"10.3233\/JAD-240479_ref74","doi-asserted-by":"crossref","first-page":"e0278412","DOI":"10.1371\/journal.pone.0278412","article-title":"Gamma frequency sensory stimulation in mild probable Alzheimer\u2019s dementia patients: Results of feasibility and pilot studies","volume":"17","author":"Chan","year":"2022","journal-title":"PLoS One"},{"key":"10.3233\/JAD-240479_ref75","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.brs.2019.11.008","article-title":"Clinical trials for deep brain stimulation: Current state of affairs","volume":"13","author":"Harmsen","year":"2020","journal-title":"Brain Stimul"},{"key":"10.3233\/JAD-240479_ref76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jare.2023.01.006","article-title":"Alzheimer\u2019s disease and synapse Loss: What can we learn from induced pluripotent stem cells?","volume":"54","author":"Rodriguez-Jimenez","year":"2023","journal-title":"J Adv Res"},{"key":"10.3233\/JAD-240479_ref77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"Acritical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-240479_ref79","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in AN interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref80","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1212\/WNL.0b013e3181e03844","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"74","author":"Laskowitz","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref81","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","article-title":"Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against Ntruncated Abeta in sporadic Alzheimer disease cases and mouse models","volume":"130","author":"Bouter","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-240479_ref82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(16)30395-7","article-title":"Solanezumab: Too late in mild Alzheimer\u2019s disease?","volume":"16","author":"The Lancet Neurology","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240479_ref83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","article-title":"Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease","volume":"36","author":"Burstein","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JAD-240479_ref84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","article-title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer\u2019s disease","volume":"2","author":"Carlson","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-240479_ref85","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1038\/s41598-021-94369-0","article-title":"BACE inhibitor treatment of mice induces hyperactivity in a Seizure-related gene 6 family dependent manner without altering learning and memory","volume":"11","author":"Nash","year":"2021","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-240479_ref86","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref87","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240479_ref88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.3233\/JAD-240479_ref89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240479_ref90","doi-asserted-by":"crossref","first-page":"166945","DOI":"10.1016\/j.bbadis.2023.166945","article-title":"The amyloid-\u03b2 peptide: Guilty as charged?","volume":"1870","author":"Murphy","year":"2004","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.3233\/JAD-240479_ref91","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3233\/JAD-220264","article-title":"Making the case for the accelerated withdrawal of aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240479_ref92","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/d41586-022-01316-8","article-title":"Will the FDA change how it vets drugs following the Alzheimer\u2019s debacle? After controversial approval for an Alzheimer\u2019s drug, lawmakers push for more oversight","volume":"605","author":"Kozlov","year":"2022","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref93","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","article-title":"Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials","volume":"28","author":"Basheer","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240479_ref94","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-240479_ref95","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240479_ref96","doi-asserted-by":"crossref","first-page":"102161","DOI":"10.1016\/j.arr.2023.102161","article-title":"Once upon a time, the Amyloid Cascade Hypothesis","volume":"93","author":"Granzotto","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240479_ref97","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-\u03b2-Amyloid drugs: A systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref98","doi-asserted-by":"crossref","first-page":"e209320","DOI":"10.1212\/WNL.0000000000209320","article-title":"Lecanemab questions","volume":"102","author":"Nadeau","year":"2024","journal-title":"Neurology"},{"key":"10.3233\/JAD-240479_ref99","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JAD-240479_ref100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-230099","article-title":"The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240479_ref101","doi-asserted-by":"crossref","first-page":"111928","DOI":"10.1016\/j.mad.2024.111928","article-title":"Unraveling the dual role of ADAM10: Bridging the gap between cancer and Alzheimer\u2019s disease","volume":"219","author":"Alexandre-Silva","year":"2024","journal-title":"Mech Ageing Dev"},{"key":"10.3233\/JAD-240479_ref102","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/febs.16870","article-title":"New insights into the function and pathophysiology of the ectodomain sheddase A Disintegrin And Metalloproteinase 10 (ADAM10)","volume":"291","author":"Rosenbaum","year":"2024","journal-title":"FEBS J"},{"key":"10.3233\/JAD-240479_ref103","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.18632\/aging.204920","article-title":"Towards disease-oriented dosing of rapamycin for longevity: Does aging exist or only age-related diseases?","volume":"15","author":"Blagosklonny","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.3233\/JAD-240479_ref104","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/15548627.2023.2175569","article-title":"Rapamycin and Alzheimer disease: A hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease","volume":"19","author":"Carosi","year":"2023","journal-title":"Autophagy"},{"key":"10.3233\/JAD-240479_ref105","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1523\/JNEUROSCI.2427-21.2022","article-title":"Microglial mTOR activation upregulates Trem2 and enhances beta-amyloid plaque clearance in the 5XFAD Alzheimer\u2019s disease model","volume":"42","author":"Shi","year":"2022","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240479_ref106","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3233\/JAD-230868","article-title":"Advanced Alzheimer\u2019s disease patients show safe, significant, and persistent benefit in 6-month bryostatin trial","volume":"96","author":"Alkon","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240479_ref107","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1073\/pnas.0509725103","article-title":"PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice","volume":"103","author":"Choi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240479_ref108","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/01.STR.0000254616.78387.ee","article-title":"Epsilon PKC may contribute to the protective effect of hypothermia in a rat focal cerebral ischemia model","volume":"38","author":"Shimohata","year":"2007","journal-title":"Stroke"},{"key":"10.3233\/JAD-240479_ref109","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.brainres.2007.09.073","article-title":"\u025bPKC phosphorylates the mitochondrial K(+) (ATP) channel during induction of ischemic preconditioning in the rat hippocampus","volume":"1184","author":"Raval","year":"2007","journal-title":"Brain Res"},{"key":"10.3233\/JAD-240479_ref110","doi-asserted-by":"crossref","first-page":"33369","DOI":"10.1074\/jbc.M103320200","article-title":"Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain","volume":"276","author":"Bajgar","year":"2021","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-240479_ref111","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05972-2","article-title":"A small-molecule PI3K\u03b1 activator for cardioprotection and neuroregeneration","volume":"618","author":"Gong","year":"2023","journal-title":"Nature"},{"key":"10.3233\/JAD-240479_ref112","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3988\/jcn.2015.11.4.297","article-title":"The Role of the PI3K pathway in the regeneration of the damaged brain by neural stem cells after cerebral infarction","volume":"11","author":"Koh","year":"2015","journal-title":"J Clin Neurol"},{"key":"10.3233\/JAD-240479_ref113","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1073\/pnas.1202810109","article-title":"Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death","volume":"109","author":"Jo","year":"2012","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.3233\/JAD-240479_ref114","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1523\/JNEUROSCI.4477-10.2011","article-title":"Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons","volume":"31","author":"Cuesto","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240479_ref115","doi-asserted-by":"crossref","first-page":"e11674","DOI":"10.15252\/emmm.201911674","article-title":"PI 3-kinase delta enhances axonal PIP3 to support regeneration in the adult CNS","volume":"12","author":"Nieuwenhuis","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-240479_ref116","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3390\/molecules25122819","article-title":"Taurine and ginsenoside Rf induce BDNF expression in SH-SY5Y cells: A potential role of BDNF in corticosterone-triggered cellular damage","volume":"25","author":"Lee","year":"2020","journal-title":"Molecules"},{"key":"10.3233\/JAD-240479_ref117","doi-asserted-by":"crossref","first-page":"eabn9257","DOI":"10.1126\/science.abn9257","article-title":"Taurine deficiency as a driver of aging","volume":"380","author":"Singh","year":"2023","journal-title":"Science"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:20Z","timestamp":1777370360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-240479"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":116,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240479","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}